Navega Therapeutics
- | Biotech or pharma, therapeutic R&D
Navega Therapeutics, a spin-off out of the University of California San Diego, is developing epigenetic gene therapies for chronic and common disease. Some company highlights: technologies from lab of Prashant Mali (co-founder of NavegaTx, ShapeTx, BoundlessTx), leading AI-enabled zinc-finger tools to modulate the epigenome for therapeutic benefit, platform technologies with the potential to overcome immune responses including novel deimmunized AAV capsids and circular-RNA technology. The company’s lead program, NT-Z001, an epigenetic gene therapy targeting Nav1.7, has shown proof-of-concept across five different models of pain, has completed safety studies in mice and in NHP. The company is raising a Series A to take NT-Z001 through human proof of concept, and to bring a second program in rheumatoid arthritis to IND.
Address
CaliforniaUnited States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}